🇺🇸 FDA
Pipeline program

NBI-98854 50 mg capsule once daily

NBI-98854-1302

Phase 1 small_molecule completed

Quick answer

NBI-98854 50 mg capsule once daily for Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects is a Phase 1 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).

Program details

Company
NEUROCRINE BIOSCIENCES INC
Indication
Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials